TY - JOUR T1 - Pharmacologic management of chronic neuropathic pain JF - Canadian Family Physician JO - Can Fam Physician SP - 844 LP - 852 VL - 63 IS - 11 AU - Alex Mu AU - Erica Weinberg AU - Dwight E. Moulin AU - Hance Clarke Y1 - 2017/11/01 UR - http://www.cfp.ca/content/63/11/844.abstract N2 - Objective To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain.Quality of evidence A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement.Main message Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.Conclusion Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain. ER -